MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer-Reference-Cited by-同舟云学术

MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer

Published:2013-11-23 Issue:10 Volume:134 Page:2424-2436
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Kim Yu Jin¹,Choi Jong-Sun²,Seo Jinwon³,Song Ji-Young¹⁴,Eun Lee Seung⁵,Kwon Mi Jung³,Kwon Mi Jeong⁶⁷,Kundu Juthika⁸,Jung Kyungsoo¹⁹,Oh Ensel¹⁴⁹,Shin Young Kee¹⁰,Choi Yoon-La¹⁴⁵⁹

Affiliation:

1. Laboratory of Cancer Genomics and Molecular Pathology; Samsung Biomedical Research Institute, Samsung Medical Center; Seoul Korea

2. Department of Pathology; Ilsan Hospital, Dongguk University; Gyeonggi Korea

3. Department of Pathology; Hallym University Sacred Heart Hospital; Hallym University College of Medicine; Gyeonggi Korea

4. Institute for Refractory Cancer Research; Samsung Medical Center; Seoul Korea

5. Department of Pathology; Samsung Medical Center, Sungkyunkwan University School of Medicine; Seoul Korea

6. College of Pharmacy; Kyungpook National University; Daegu Korea

7. Research Institute of Pharmaceutical Sciences; College of Pharmacy, Kyungpook National University; Daegu Korea

8. College of Pharmacy; Keimyung University; Daegu Korea

9. Samsung Advanced Institute for Health Sciences & Technology; Sungkyunkwan University School of Medicine; Seoul Korea

10. Laboratory of Molecular Pathology and Cancer Genomics, Department of Pharmacy; College of Pharmacy, Seoul National University; Seoul Korea

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference45 articles.

1. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011;Goldhirsch;Ann Oncol,2011

2. Use of standard markers and incorporation of molecular markers into breast cancer therapy: consensus recommendations from an International Expert Panel;Kaufmann;Cancer,2011

3. Triple-negative breast cancer;Foulkes;N Engl J Med,2010

4. Repeated observation of breast tumor subtypes in independent gene expression data sets;Sorlie;Proc Natl Acad Sci USA,2003

5. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma;Nielsen;Clin Cancer Res,2004

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Machine learning-based QSAR modeling, molecular docking, dynamics simulation studies for cytotoxicity prediction in MDA-MB231 triple-negative breast cancer cell line;Journal of Molecular Structure;2024-11

2. Senescence-related genes analysis in breast cancer reveals the immune microenvironment and implications for immunotherapy;Aging;2024-02-14

3. c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer;Breast Cancer Research;2024-01-18

4. Targeting Receptor Tyrosine Kinases as a Novel Strategy for the Treatment of Triple-Negative Breast Cancer;Technology in Cancer Research & Treatment;2024-01

5. Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR;Journal of Experimental & Clinical Cancer Research;2023-11-04